Literature DB >> 19773679

The use of human papillomavirus seroepidemiology to inform vaccine policy.

Mark Schiffman, Mahboobeh Safaeian, Nicolas Wentzensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19773679      PMCID： PMC4237610          DOI： 10.1097/OLQ.0b013e3181bce102

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


× No keyword cloud information.
  17 in total

1.  Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients.

Authors:  J Slavinsky; P Kissinger; L Burger; A Boley; R P DiCarlo; M E Hagensee
Journal:  Int J STD AIDS       Date:  2001-08       Impact factor: 1.359

2.  Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.

Authors:  M D Yeager; M Aste-Amezaga; D R Brown; M M Martin; M J Shah; J C Cook; N D Christensen; C Ackerson; R S Lowe; J F Smith; P Keller; K U Jansen
Journal:  Virology       Date:  2000-12-20       Impact factor: 3.616

3.  Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.

Authors:  M E Hagensee; L A Koutsky; S K Lee; T Grubert; J Kuypers; N B Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-04-07       Impact factor: 5.226

4.  Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Authors:  Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

5.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.

Authors:  Peter Sehr; Martin Müller; Reinhard Höpfl; Andreas Widschwendter; Michael Pawlita
Journal:  J Virol Methods       Date:  2002-10       Impact factor: 2.014

7.  HPV 6/11, 16, 18 seroprevalence in men in two US cities.

Authors:  Eileen F Dunne; Carrie M Nielson; Michael E Hagensee; Mary R Papenfuss; Robin B Harris; Nicholas Herrel; Jennifer Gourlie; Martha Abrahamsen; Lauri E Markowitz; Anna R Giuliano
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

8.  Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Authors:  David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

9.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

10.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; T S Shields; R Herrero; A Hildesheim; M C Bratti; M E Sherman; A C Rodriguez; P E Castle; J Morales; M Alfaro; T Wright; S Chen; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640
View more
  14 in total

1.  Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Authors:  Sarah E Coseo; Carolina Porras; Lori E Dodd; Allan Hildesheim; Ana Cecilia Rodriguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Silvia Jimenez; Diane Solomon; Catherine Bougelet; Leen-Jan van Doorn; Wim Quint; Mahboobeh Safaeian
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

Review 2.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

3.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Authors:  Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

4.  A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.

Authors:  Hormuzd A Katki; Li C Cheung; Barbara Fetterman; Philip E Castle; Rajeshwari Sundaram
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2015-03-17       Impact factor: 2.483

5.  Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.

Authors:  Arezoo Aghakhani; Setareh Mamishi; Shahram Sabeti; Farahnaz Bidari-Zerehpoosh; Mohammad Banifazl; Anahita Bavand; Amitis Ramezani
Journal:  Med Microbiol Immunol       Date:  2016-11-17       Impact factor: 3.402

Review 6.  The known unknowns of HPV natural history.

Authors:  Patti E Gravitt
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

7.  A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

Authors:  Nicolas Wentzensen; Ana Cecilia Rodriguez; Raphael Viscidi; Rolando Herrero; Allan Hildesheim; Arpita Ghosh; Jorge Morales; Sholom Wacholder; Diego Guillen; Mario Alfaro; Mahboobeh Safaeian; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

8.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

9.  Human papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African women.

Authors:  Frank Tanser; Kyle G Jones; Johannes Viljoen; John Imrie; Erofili Grapsa; Marie-Louise Newell
Journal:  Sex Transm Dis       Date:  2013-07       Impact factor: 2.830

10.  Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Wim G V Quint; Maurits N C de Koning; Mark Schiffman
Journal:  Int J Cancer       Date:  2013-04-05       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.